XML 32 R21.htm IDEA: XBRL DOCUMENT v3.19.2
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 3 Months Ended
Jun. 29, 2019
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION
15. SEGMENT AND ENTERPRISE-WIDE INFORMATION

The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Historically, the Company's operating segments were based primarily on geography. Effective as of March 31, 2019, the Company completed the transition of its operating structuring to three global business units and accordingly has reorganized its reporting structure to align with its three global business units and the information that will be regularly reviewed by the Company's chief operating decision maker.

Following the reorganization, the Company's reportable segments are as follows:
•
Plasma
•
Blood Center
•
Hospital

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, asset impairments, accelerated depreciation, certain transaction costs and legal charges. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

Selected information by reportable segment is presented below:
 
Three Months Ended
(In thousands)
June 29,
2019
 
June 30,
2018
Net revenues
 
 
 
Plasma
$
110,763

 
$
99,290

Blood Center
77,996

 
79,818

Hospital
47,187

 
45,845

Net revenues by business unit
235,946

 
224,953

Service (1)
4,866

 
4,325

Effect of exchange rates
(2,361
)
 
69

Net revenues
$
238,451

 
$
229,347

(1) Reflects revenue for service, maintenance and parts
 
Three Months Ended
(In thousands)
June 29,
2019
 
June 30,
2018
Segment operating income
 
 
 
Plasma
$
53,725

 
$
41,921

Blood Center
37,719

 
38,472

Hospital
18,916

 
18,328

Segment operating income
110,360

 
98,721

  Corporate expenses (1)
(61,703
)
 
(61,050
)
  Effect of exchange rates
2,769

 
3,055

Impairment of assets and other related charges
(51,166
)
 
(21,170
)
Deal amortization
(5,974
)
 
(6,300
)
PCS2 accelerated depreciation and related costs
(5,528
)
 
(3,939
)
Restructuring and turnaround costs
(2,027
)
 
(3,349
)
Other
(33
)
 
(675
)
Operating (loss) income
$
(13,302
)
 
$
5,293

(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.

(In thousands)
June 29,
2019
 
March 30,
2019
Long-lived assets(1)
 
 
 
Plasma
$
168,816

 
$
209,827

Blood Center
88,560

 
110,073

Hospital
19,372

 
24,079

Total long-lived assets
$
276,748

 
$
343,979

(1) Long-lived assets are comprised of property, plant and equipment.


Management reviews revenue based on the reportable segments noted above.  Although these reportable segments are primarily product-based, they differ from the Company’s product line revenues for Plasma products and services and Blood Center products and services.  Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes.  Additionally, product line revenues also include service revenues which are excluded from the reportable segments.

Net revenues by product line are as follows:
 
Three Months Ended
(In thousands)
June 29,
2019
 
June 30,
2018
Plasma products and services
$
129,745

 
$
116,903

Blood Center products and services
59,907

 
64,483

Hospital products and services
48,799

 
47,961

Net revenues
$
238,451

 
$
229,347

Net revenues generated in the Company's principle operating regions on a reported basis are as follows:
 
Three Months Ended
(In thousands)
June 29,
2019
 
June 30,
2018
United States
$
156,375

 
$
142,140

Japan
15,467

 
17,389

Europe
36,753

 
39,002

Asia
28,641

 
29,395

Other
1,215

 
1,421

Net revenues
$
238,451

 
$
229,347